Oxonol & MGM-15 Guide: 7-OH, DEA Status and MIT

Oxonol is a commercial product-line name, not the scientific name of a single alkaloid. The manufacturer description cited in this guide identifies MGM-15 and mitragynine in the chewable-tablet formula. That distinction matters because DEA's August 26, 2026 temporary order names MGM-15 directly even though it does not use the retail name Oxonol.

Oxonol, MGM-15, and mitragynine are not interchangeable names

A front-label brand can remain the same while a formulation, strength, or package changes. An ingredient name is more specific. The manufacturer’s own description calls Oxonol a brand name and identifies MGM-15 and mitragynine as its active ingredients. DEA separately identifies MGM-15 as dihydro-7-hydroxymitragynine and describes it as a synthetic derivative of 7-hydroxymitragynine.

What research says about MGM-15's human-effects potential

MGM-15 is not a neutral branding ingredient. A 2025 peer-reviewed study analyzed commercial MGM-labeled tablets and found an average of 10.9 milligrams of MGM-15 per tablet. In receptor testing, purified MGM-15 showed greater binding affinity at human mu- and delta-opioid receptors than 7-OH. The authors warned of potentially greater opioid effects and risks. The study did not administer MGM-15 to people, so controlled human safety, pharmacokinetics, and dose-response data remain absent.

That evidence helps explain why MGM-15 entered the same public-health conversation as 7-OH. Commercial chewable tablets are intended for ingestion, but higher receptor affinity does not translate into a precise human potency multiplier or a clinical benefit. With no controlled human-administration data, claims such as “gentler,” “safer,” or “just another kratom extract” are not established.

The comparison with MIT is substantive. Mitragynine is a naturally occurring psychoactive kratom alkaloid, while MGM-15 is a synthetic 7-OH derivative engineered for stronger receptor activity. MIT is not risk-free, but it has a different compound identity and evidence base.

What the DEA temporary order says about MGM-15

DEA's temporary order placed MGM-15, mitragynine pseudoindoxyl, and MGM-16 in Schedule I effective August 26, 2026. The order runs through August 26, 2028 unless it is extended or made permanent. It identifies the named substances and covered forms; it does not need to list every retail brand that may contain one of them.

It is equally inaccurate to treat MGM-15 as outside the federal action simply because a package uses a brand name. Regulatory documents generally identify substances rather than every retail brand containing them. Read the ingredient panel and current formula alongside the current government document.

Why MIT belongs in a different product-identity lane

Mitragynine is a naturally occurring alkaloid of the kratom plant. DEA’s MGM-15 notice expressly contrasts naturally occurring mitragynine with MGM-15, MGM-16, and mitragynine pseudoindoxyl, which it describes as synthetic derivatives produced through chemical modifications of purified isolates. A concentrated MIT extract is still an extract and should be identified with its percentage, units, package size, and document scope, but MIT is not another name for MGM-15.

Kratom Paradise MIT tablets and MIT extract powder are presented with distinct product identities and distinct records. The current finished-tablet report covers pressed Mitragynine Tablet lot M/150/002 and lists 146 mg mitragynine per unit; the current MIT 90% extract-powder report covers sample DD00126B(15) / SD260715-011 (142956) and lists 87.01% mitragynine. Those records do not turn the products into approved drugs or establish equivalence to 7-OH.

Five fields to check on an Oxonol or MGM-15 product

1. Brand and manufacturer: record the company and exact product-line name.
2. Ingredient identity: look for MGM-15, dihydro-7-hydroxymitragynine, mitragynine, 7-OH, pseudoindoxyl, or a mixture.
3. Units and basis: keep milligrams per tablet, total package amount, percentage, and net weight separate.
4. Formula date: product pages and packaging can change; save the version and date you reviewed.
5. Regulatory date: distinguish DEA's effective August 26 order for the three named substances from the separate proposed-threshold process for 7-OH, and check state and local rules separately.

Does “legal 7-OH alternative” settle the question?

No. “Legal” depends on the named substance, formula, place, and date. “Alternative” can describe a merchandising position without proving chemical identity, legal status, safety, or comparable effects. DEA's August 26 temporary order is directly relevant to any product described as containing MGM-15, while the separate proposed-threshold process for 7-OH remains distinct.

For the manufacturer’s description of the Oxonol name and formula, review its current product explainer. Treat that page as the seller’s own account, not independent scientific or legal confirmation.

Where to go next

Use our Oxonol vs MIT vs 7-OH comparison for a side-by-side identity check, the DEA 7-OH scheduling tracker for dated updates, and the MIT products guide for current tablet and powder formats.

For product and regulatory education only; not medical or legal advice. Kratom Paradise does not sell Oxonol or MGM-15 products.